<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327664</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457C2399</org_study_id>
    <secondary_id>2010-021239-15</secondary_id>
    <nct_id>NCT01327664</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis</brief_title>
  <acronym>SUPPORT</acronym>
  <official_title>A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will provide patients who have completed the AIN457 Phase II and Phase III
      clinical trials in non-infectious uveitis continued access to treatment with AIN457 while
      collecting safety data and information on long term clinical use of treatment with AIN457.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study will not be initiated as planned.
  </why_stopped>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients achieving the criteria for clinically inactive posterior segment uveitis</measure>
    <time_frame>up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time to achieve the criteria for clinically inactive posterior segment uveitis</measure>
    <time_frame>up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing clinically active posterior segment uveitis in patients discontinuing AIN457 treatment</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of clinically active posterior segment uveitis after discontinuation of AIN457 treatment</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of a recurrence of clinically active posterior segment uveitis in patients discontinuing AIN457 and treated only with the reinitiation of AIN457</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>AIN457 300mg s.c every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <arm_group_label>AIN457 300mg s.c every 2 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to understand and communicate with the investigator and comply
             with the requirements for the study and must give a written, signed, and dated
             informed consent before any study assessment is performed

          -  Patient is currently enrolled in CAIN457A2208 or has completed the core and extension
             study treatment periods in the ongoing AIN457 phase III clinical trial Studies (e.g.,
             CAIN457C2301 and CAIN457C2301E1)

          -  Willingness to discontinue AIN457 or be weaned from standard of care immunosuppressive
             therapy if recommended by the study investigator

        Exclusion Criteria:

          -  Need for treatment with ocular procedures or systemic medications prohibited in this
             study including an alkylating agent or another biologic therapy other than AIN457

          -  Pregnant or nursing (lactating) women

          -  Women of childbearing potential unwilling to use protocol defined acceptable methods
             of contraception throughout the study and for 16 weeks after study drug
             discontinuation

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals Corporation</organization>
  </responsible_party>
  <keyword>Quiescent uveitis</keyword>
  <keyword>intermediate uveitis</keyword>
  <keyword>panuveitis</keyword>
  <keyword>posterior uveitis</keyword>
  <keyword>uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

